march 21 reuters head wellpoint incs commercial business said friday price new hepatitis c drugs made gilead sciences inc johnson johnson high
ken goulet speaking investors said company working regulators drug manufacturers bring prices reasonable level
said midfebruary company filled 100 prescriptions commercial members
medicaid side business wellpoint said working states trying determine proceed either figuring managed care cost drug excluding drug managed care plans reporting caroline humer editing franklin paul
